Leronlimab is being tested to treat some of the world's most urgent health challenges.
“Leronlimab halted the inflammation and blood clotting that are so damaging to the lungs, liver and kidneys of severely ill COVID-19 patients.”

-- Harish Seethamraju, M.D. Albert Einstein College of Medicine Montefiore

Disclaimer: This website is not affiliated with CytoDyn Inc.

The only way I can explain it is, it was like it felt like I had 1,000 cups of coffee,” said Recknor. “And then after the medicine, it was like a relaxing time on the beach. A couple days after the medicine, I was back to doing everything normal. I knew there were other people like me having crazy symptoms.
— Dr. Chris Recknor, a Gainesville internist who received leronlimab during his COVID-19 infection. Quote via @AJC
In the News

August 11, 2020

CytoDyn Announces Top-line Efficacy Results:

Leronlimab Improved NEWS2 by 50%

Patients in the leronlimab group were more than twice as likely to experience a beneficial improvement in scores compared to patients in the placebo group.

Leronlimab Reduced Severe Adverse Effects

"39% (11 SAEs in 28 Patients) in Placebo Arm as Compared to Only 14% (8 SAEs in 56 Patients) in Leronlimab Arm Reported Serious Adverse Events (SAEs), Which Were Unrelated to Leronlimab. The Efficacy Portion of the Trial Will Be Announced Along With a Full Report as Soon as Statistical Analyses Are Completed"

Recent News Coverage:

CytoDyn touts ‘impressive’ early results for virus drug: Biotech company’s Leronlimab may aid in symptom control:


Scientists are making headway in the hunt for COVID-19 treatments and vaccines and North Texans are being asked to be a part of it:


Video supplement: https://youtu.be/sJAdnCROf2U

Related: https://www.trialsitenews.com/baylor-university-medical-center-investigates-safety-efficacy-of-leronlimab-in-severe-to-critical-covid-19-patients/

as featured in